Bioqube Ventures

Bioqube Ventures NV is a venture capital firm based in Brussels, Belgium, established in 2016. The company specializes in early-stage investments in the life sciences sector, particularly targeting European biotech companies that are developing innovative therapeutic assets and technologies. Bioqube Ventures focuses on investments in the Benelux countries, France, and Germany, aiming to advance scientific innovation and support companies with medicines in the testing phase. The firm employs a dual investment model that includes traditional early investment rounds and special attention to projects that require additional de-risking before launching new ventures. With a diverse team of fund managers, sector experts, and serial entrepreneurs, Bioqube Ventures takes a hands-on approach to drive growth and maximize value for its portfolio companies and investors.

Alexander Demoulin

Associate

Debora Dumont

Co-Founder and Managing Partner

Jacques Mizrahi

Venture Partner

Dirk Reyn

Managing Partner

Clement Salque

Junior Associate

Joris Vanderlocht

Chief Scientific Director

Nico Vandervelpen

Co-Founder and Managing Partner

Roderick Verhelst

Principal

Past deals in Denmark

Commit Biologics

Seed Round in 2025
Commit Biologics is a biotechnology research company based in Aarhus, Denmark, founded in 2021. The company focuses on developing a novel immunotherapy platform designed for the treatment of various cancers. This platform utilizes b-specific domain antibodies, which are engineered to effectively target and kill tumor cells. The technology is modular, allowing for customization to engage the body's innate immune response. By activating the complement component of the immune system, Commit Biologics aims to provide innovative treatment options for both cancer and autoimmune diseases.

Commit Biologics

Seed Round in 2024
Commit Biologics is a biotechnology research company based in Aarhus, Denmark, founded in 2021. The company focuses on developing a novel immunotherapy platform designed for the treatment of various cancers. This platform utilizes b-specific domain antibodies, which are engineered to effectively target and kill tumor cells. The technology is modular, allowing for customization to engage the body's innate immune response. By activating the complement component of the immune system, Commit Biologics aims to provide innovative treatment options for both cancer and autoimmune diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.